Skip to content

Rafael Holdings, Inc. RFL Product Revenue — Revenue

Other product segments

Rental Third Party
$60K+22.4%
Rental Related Party
$30K+7.1%

Similar metrics at other companies

Cumberland Pharmaceuticals logo
CPIXProduct — Revenue
$10.1M+10.6%
Ondas, Inc.
 logo
ONDSProduct Revenue — Revenue
$38.37M+1,090%
Bausch Health Companies logo
BHCProduct sales — Revenue
$2.5B+12.3%
Pfizer logo
PFEProduct — Revenue
$11.72B+3.7%
Organogenesis Holdings Inc. logo
ORGOProduct — Revenue
$36.25M-58.2%
TransMedics Group, Inc. logo
TMDXProduct — Revenue
$107.97M+22.4%

Other financials

Income statement

See full
Revenue$179.0K-50.6%
Gross profit$131.0K-56.3%
Operating income-$6.9M-16.2%
Net income-$4.2M+11.6%
EPS (diluted)-$0.08+57.9%

Balance sheet

See full
Cash & equivalents$30.5M-19.6%
Total debt$21.9M+995%
Total equity$75.4M-6.4%
Total assets$92.0M-14.9%

Cash flow

See full
Operating cash flow-$7.3M-128%
CapEx$6.0K
Free cash flow-$7.3M-128%

Valuation

See full
Market cap$170.56M+189%
P/S174×+93.5×

Profitability

See full
Gross margin71.9%
Operating margin-3,717.2%+1,952pp
Net margin-2,117.2%-517pp
FCF margin-2,064.1%

Returns & leverage

See full
Return on equity-26.6%-0.8pp
Debt / equity0.3×+0.2×
Current ratio3.2×-0.7×

Where this comes from

Reported directly by Rafael Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Rafael Holdings, Inc.’s 10-Q, filed June 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rafael Holdings, Inc.'s product revenue — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rafael Holdings, Inc.'s product revenue — revenue?
Rafael Holdings, Inc. (RFL) reported product revenue — revenue of $89K in Q1 2026.
What does product revenue — revenue mean?
This metric represents the total gross income generated from the sale of pharmaceutical products or clinical therapies within the specific business segment. It reflects the company's ability to monetize its oncology-focused research and development pipeline through commercialized offerings. Tracking this figure helps investors assess the market adoption and revenue-generating potential of the company's therapeutic portfolio.